In parts of Africa, up to 75 percent of the babies born stand to lose their mothers, who are HIV-positive, to AIDS-related illnesses. Without intervention, more than a quarter of these children will also acquire the virus. An entire generation is at stake. –mothers2mothers

{ banner }

CONRAD's Mission

To help improve reproductive health globally by enabling prevention of HIV and sexually transmitted infections, unintended pregnancies and maternal/neonatal disease through the development of innovative, user-centered technologies suitable for use by people living in resource-constrained regions of the world.

Our accomplishments include:

  • Conducted pivotal clinical trials for registration of barrier methods of contraception, most recently the Caya one-size-fits-most diaphragm, which is currently sold in the U.S. and Europe
  • CONRAD sponsored late phase studies, including FACTS 001 and CAPRISA 004 which tested the use of tenofovir gel for HIV prevention in women, the male contraceptive trial of TU/NE, and the first generation microbicide trial of cellulose sulfate.
  • Developed pipeline of novel male and female contraceptive leads
  • Pioneered public/private partnerships in contraceptive R&D
  • Designed preclinical models and algorithms for testing products
  • Developed new microbicide delivery systems
  • Provided product development, manufacturing, and preclinical testing capacity to other organizations (private and public)
  • Developed and tested contraceptive, microbicide and dual- protection candidates following an integrated preclinical/clinical system
  • Introduced innovation in early candidate assessment

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 | info@conrad.org